BDTX Live signals | Maximize Profits with Getagraph.com

BUY 136456 min ago

@ $4.67

Issued: 14 Feb 2024 @ 13:53

Return: 4.28%

Previous signal: Feb 13 - 15:50

Previous signal: Sell

Return: 11.73 %

Live Chart Being Loaded With Signals

Commentary (17 May 2024 @ 16:00):

Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors...

Stats
Today's Volume	1.24M
Average Volume	656 755
Market Cap	273.95M
EPS	$0 ( 2024-05-14 )
Next earnings date	( $-0.430 ) 2024-06-06
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.93
ATR14	$0.00800 (0.16%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-10	Campbell Shannon	Buy	61 100	Stock Option (Right to Buy)
2024-04-10	Raman Prakash	Buy	61 100	Stock Option (Right to Buy)
2024-04-10	Campbell Shannon	Buy	0
2024-04-10	Raman Prakash	Buy	0
2024-03-15	Behbahani Ali	Buy	3 166	Common Stock

INSIDER POWER
99.07
Last 97 transactions
Buy: 11 965 700 \| Sell: 275 000

Volume Correlation

Long: 0.14 (neutral)

Short: 0.46 (neutral)

Signal:(40.518) Neutral

Black Diamond Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Black Diamond Correlation - Currency/Commodity

-0.50
( neutral )

-0.64
( weak negative )

0.00
( neutral )

-0.05
( neutral )

0.62
( weak )

Black Diamond Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-437 000 (0.00 %)
EPS:	$-1.880

FY	2023
Revenue:	$0
Gross Profit:	$-437 000 (0.00 %)
EPS:	$-1.880

FY	2022
Revenue:	$0
Gross Profit:	$-3.24M (0.00 %)
EPS:	$-2.33

FY	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-0.00347

Financial Reports:

No articles found.

Black Diamond Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Black Diamond

Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 driver mutations. The company is also developing BDTX-1535, a brain-penetrant inhibitor of EGFR mutations, including canonical, intrinsic resistance, and acquired resistance mutations; and BDTX-4933, a brain-penetrant inhibitor of oncogenic BRAF class I, II and III alterations. It has a strategic partnership with OpenEye Scientific Software, Inc. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.